Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
4
×
national blog main
boston
boston blog main
clinical trials
biotech
boston top stories
europe blog main
europe top stories
fda
abaloparatide
acute hepatic porphyrias
akin akinc
alnylam pharmaceuticals
amgen
aminolevulinic acid
andrew berens
avapritinib
biopharma
blueprint medicines
cancer
deals
deciphera pharmaceuticals
drugs
duchenne
european commission
gastrointestinal stromal tumor
gist
givosiran
gleevec
imatinib
licensing
m&a
muscular dystrophy
national
national top stories
onpattro
osteoporosis
patisiran
paul matteis
What
approval
4
×
medicine
4
×
drug
fda
nod
rna
second
seek
ago
alnylam
amgen
amgen’s
announced
betting
billion
biopharma
blueprint
cancer
carries
chasing
deadly
deal
deciphera
developed
duchenne
europe
european
filing
forms
gene
gi
heart
historic
indicated
interference
marketing
morning
osteoporosis
pharamceuticals
pharmaceuticals
Language
unset
Current search:
xconomy.com
×
medicine
×
" life sciences "
×
approval
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug